» Articles » PMID: 37101547

Ginsenoside Rg1 Can Reverse Fatigue Behavior in CFS Rats by Regulating EGFR and Affecting Taurine and Mannose 6-phosphate Metabolism

Overview
Journal Front Pharmacol
Date 2023 Apr 27
PMID 37101547
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic fatigue syndrome (CFS) is characterized by significant and persistent fatigue. Ginseng is a traditional anti-fatigue Chinese medicine with a long history in Asia, as demonstrated by clinical and experimental studies. Ginsenoside Rg1 is mainly derived from ginseng, and its anti-fatigue metabolic mechanism has not been thoroughly explored. We performed non-targeted metabolomics of rat serum using LC-MS and multivariate data analysis to identify potential biomarkers and metabolic pathways. In addition, we implemented network pharmacological analysis to reveal the potential target of ginsenoside Rg1 in CFS rats. The expression levels of target proteins were measured by PCR and Western blotting. Metabolomics analysis confirmed metabolic disorders in the serum of CFS rats. Ginsenoside Rg1 can regulate metabolic pathways to reverse metabolic biases in CFS rats. We found a total of 34 biomarkers, including key markers Taurine and Mannose 6-phosphate. AKT1, VEGFA and EGFR were identified as anti-fatigue targets of ginsenoside Rg1 using network pharmacological analysis. Finally, biological analysis showed that ginsenoside Rg1 was able to down-regulate the expression of EGFR. Our results suggest ginsenoside Rg1 has an anti-fatigue effect, impacting the metabolism of Taurine and Mannose 6-phosphate through EGFR regulation. This demonstrates ginsenoside Rg1 is a promising alternative treatment for patients presenting with chronic fatigue syndrome.

Citing Articles

Preliminary investigation of anti-fatigue effects and potential mechanisms of meiju oral liquid in mouse and zebrafish models.

Zhang L, Zhao J, Zhou X, Maiwulanjiang M PLoS One. 2025; 20(3):e0316761.

PMID: 40048455 PMC: 11884715. DOI: 10.1371/journal.pone.0316761.


A novel strategy for the protective effect of ginsenoside Rg1 against ovarian reserve decline by the PINK1 pathway.

Yang P, Fan M, Chen Y, Yang D, Zhai L, Fu B Pharm Biol. 2025; 63(1):68-81.

PMID: 39862058 PMC: 11770866. DOI: 10.1080/13880209.2025.2453699.


Study on the effects of Massa Medicata Fermentata with different formulations on the intestinal microbiota and enzyme activities in mice with spleen deficiency constipation.

Liang X, Wan D, Li X, Peng Y, Chen L Front Cell Infect Microbiol. 2025; 14():1524327.

PMID: 39844840 PMC: 11753248. DOI: 10.3389/fcimb.2024.1524327.


Insights into the Therapeutic Potential of Active Ingredients of in Combatting Sarcopenia: An In Silico Approach.

Ullah A, Bo Y, Li J, Li J, Khatun P, Lyu Q Int J Mol Sci. 2024; 25(21).

PMID: 39519004 PMC: 11546236. DOI: 10.3390/ijms252111451.


Chronic Fatigue Syndrome: Diagnosis, Treatment, and Future Direction.

Graves B, Patel M, Newgent H, Parvathy G, Nasri A, Moxam J Cureus. 2024; 16(10):e70616.

PMID: 39483544 PMC: 11526618. DOI: 10.7759/cureus.70616.


References
1.
Yousuf S, Liu H, Yingshu Z, Zahid D, Ghayas H, Li M . Ginsenoside Rg1 modulates intestinal microbiota and supports re-generation of immune cells in dexamethasone-treated mice. Acta Microbiol Immunol Hung. 2022; 69(4):259-269. DOI: 10.1556/030.2022.01881. View

2.
Kennedy G, Spence V, McLaren M, Hill A, Underwood C, Belch J . Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med. 2005; 39(5):584-9. DOI: 10.1016/j.freeradbiomed.2005.04.020. View

3.
Bornstein S, Voit-Bak K, Donate T, Rodionov R, Gainetdinov R, Tselmin S . Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Mol Psychiatry. 2021; 27(1):34-37. PMC: 8209771. DOI: 10.1038/s41380-021-01148-4. View

4.
Yang J, Shin K, Abu Dabrh A, Bierle D, Zhou X, Bauer B . Ginseng for the Treatment of Chronic Fatigue Syndrome: A Systematic Review of Clinical Studies. Glob Adv Health Med. 2022; 11:2164957X221079790. PMC: 8848096. DOI: 10.1177/2164957X221079790. View

5.
Landi A, Broadhurst D, Vernon S, Tyrrell D, Houghton M . Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. Cytokine. 2015; 78:27-36. DOI: 10.1016/j.cyto.2015.11.018. View